- Report
- January 2024
- 285 Pages
Global
From €9243EUR$9,500USD£7,918GBP
- Report
- February 2024
- 115 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- March 2024
- 30 Pages
Global
From €3162EUR$3,250USD£2,709GBP
- Report
- January 2024
- 180 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2024
- 200 Pages
Global
From €4038EUR$4,150USD£3,459GBP
- Report
- April 2018
Global
From €973EUR$1,000USD£834GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2335EUR$2,400USD£2,000GBP
- Report
- February 2024
- 112 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- April 2024
- 50 Pages
Global
From €2578EUR$2,650USD£2,209GBP
- Report
- November 2021
- 844 Pages
Global
From €4865EUR$5,000USD£4,168GBP
Pramipexole is a dopamine agonist used to treat symptoms of Parkinson's disease, restless leg syndrome, and other conditions. It is a member of the class of drugs known as central nervous system (CNS) drugs, which are used to treat neurological disorders. Pramipexole works by activating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease and other conditions. It is available in both immediate-release and extended-release formulations.
Pramipexole is a widely used CNS drug, with a large market share in the United States and Europe. It is available in both generic and branded forms, and is prescribed by doctors for the treatment of Parkinson's disease and other neurological disorders.
Several companies are involved in the Pramipexole market, including Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies involved in the market include Actavis, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more
